| 1 | Liver Transplantation in Well‐Selected Class III Obese Recipients Yields Good Outcomes | 1.0 | 0 | Citations (PDF) |
| 2 | THU-246 Safety, tolerability and immunogenicity of GS-2829 and GS-6779, a novel arenaviral vectored therapeutic hepatitis B vaccine: results from a phase 1a study in healthy participants | 7.4 | 0 | Citations (PDF) |
| 3 | THU-254 First-in-human pharmacokinetics and pharmacodynamics of oral small-molecule PD-L1 inhibitor AB-101 and correlation to preclinical models | 7.4 | 0 | Citations (PDF) |
| 4 | THU-261 Monotherapy with the novel capsid assembly modulator ALG- 000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection | 7.4 | 2 | Citations (PDF) |
| 5 | THU-245 Safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7565020, a novel monoclonal antibody that targets the hepatitis B surface antigen: results from a phase 1 single ascending dose study in healthy volunteers and participants with chronic hepatitis B | 7.4 | 2 | Citations (PDF) |
| 6 | Graft versus host disease after liver transplantation: A single center case series | 0.4 | 0 | Citations (PDF) |
| 7 | Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety | 0.6 | 61 | Citations (PDF) |
| 8 | Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses | 3.5 | 4 | Citations (PDF) |
| 9 | Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial | 22.8 | 249 | Citations (PDF) |
| 10 | WED-361 Dosing with the Capsid Assembly Modulator ALG-000184 in Untreated HBeAg Negative CHB Subjects Results in Potent Antiviral Effects Including Suppression of HBV DNA/RNA and Declines in HBcrAg Levels | 7.4 | 2 | Citations (PDF) |
| 11 | WED-378 Association of baseline characteristics and plasma ALG-001075 to HBsAg responses in HBeAg+ CHB subjects following ALG-000184 ± ETV treatment | 7.4 | 0 | Citations (PDF) |
| 12 | Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection | 1.0 | 4 | Citations (PDF) |
| 13 | Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study | 1.2 | 7 | Citations (PDF) |
| 14 | Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression | 7.4 | 67 | Citations (PDF) |
| 15 | Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants | 1.8 | 5 | Citations (PDF) |
| 16 | Evaluation of RNAi therapeutics VIR-2218 and ALN-HBV for chronic hepatitis B: Results from randomized clinical trials | 7.4 | 99 | Citations (PDF) |
| 17 | Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis | 8.1 | 8 | Citations (PDF) |
| 18 | A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults | 1.8 | 2 | Citations (PDF) |
| 19 | Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study | 3.5 | 11 | Citations (PDF) |
| 20 | Reinfection incidence and risk among people treated for recent hepatitis C virus infectionAids, 2023, 37, 1883-1890 | 1.5 | 14 | Citations (PDF) |
| 21 | The roadmap towards cure of chronic hepatitis B virus infection | 1.9 | 5 | Citations (PDF) |
| 22 | Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine | 5.3 | 12 | Citations (PDF) |
| 23 | Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long‐term follow‐up study | 3.1 | 3 | Citations (PDF) |
| 24 | Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection | 2.6 | 18 | Citations (PDF) |
| 25 | JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B | 1.8 | 15 | Citations (PDF) |
| 26 | Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) | 7.4 | 7 | Citations (PDF) |
| 27 | Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis | 7.4 | 0 | Citations (PDF) |
| 28 | Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection | 7.4 | 11 | Citations (PDF) |
| 29 | In vivo CRISPR/Cas9 editing of the TTR gene with NTLA-2001 in patients with transthyretin amyloidosis- dose selection considerations | 7.4 | 6 | Citations (PDF) |
| 30 | IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study | 7.4 | 5 | Citations (PDF) |
| 31 | Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody | 7.4 | 12 | Citations (PDF) |
| 32 | Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B | 7.4 | 1 | Citations (PDF) |
| 33 | Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients | 7.4 | 7 | Citations (PDF) |
| 34 | Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells | 7.4 | 11 | Citations (PDF) |
| 35 | Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects | 7.4 | 1 | Citations (PDF) |
| 36 | Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B | 7.4 | 9 | Citations (PDF) |
| 37 | The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New Zealand | 1.3 | 8 | Citations (PDF) |
| 38 | Glecaprevir/pibrentasvir and sofosbuvir for 16 weeks without ribavirin is safe and highly effective retreatment for patients who have failed an NS5A inhibitor containing antiviral regimen | 7.4 | 2 | Citations (PDF) |
| 39 | Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients | 7.4 | 4 | Citations (PDF) |
| 40 | Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow-up | 7.4 | 5 | Citations (PDF) |
| 41 | Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment naïve patients with HBeAg positive chronic hepatitis B | 7.4 | 1 | Citations (PDF) |
| 42 | Acute variceal bleeding portends poor outcomes in patients with acute-on-chronic liver failure: a propensity score matched study from the APASL ACLF Research Consortium (AARC) | 3.2 | 19 | Citations (PDF) |
| 43 | Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study | 7.4 | 3 | Citations (PDF) |
| 44 | Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects | 7.4 | 10 | Citations (PDF) |
| 45 | Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase | 9.5 | 10 | Citations (PDF) |
| 46 | Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients | 3.2 | 29 | Citations (PDF) |
| 47 | Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials | 1.2 | 30 | Citations (PDF) |
| 48 | Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure | 3.2 | 13 | Citations (PDF) |
| 49 | Outcomes of Treatment for Hepatitis C in Primary Care, Compared to Hospital-based Care: A Randomized, Controlled Trial in People Who Inject Drugs | 3.8 | 83 | Citations (PDF) |
| 50 | Short‐Duration Pan‐Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection | 9.5 | 41 | Citations (PDF) |
| 51 | Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial | 14.9 | 105 | Citations (PDF) |
| 52 | Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy | 3.8 | 63 | Citations (PDF) |
| 53 | Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial | 7.4 | 45 | Citations (PDF) |
| 54 | Current perspectives on the tumor microenvironment in hepatocellular carcinoma | 3.2 | 75 | Citations (PDF) |
| 55 | Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients | 1.7 | 37 | Citations (PDF) |
| 56 | A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants | 2.4 | 21 | Citations (PDF) |
| 57 | HBV variants are common in the ‘immune‐tolerant’ phase of chronic hepatitis B | 1.2 | 12 | Citations (PDF) |
| 58 | Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy | 10.7 | 487 | Citations (PDF) |
| 59 | Twelve weeks of ledipasvir/sofosbuvir all‐oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials | 1.9 | 7 | Citations (PDF) |
| 60 | Prevalence of Hepatitis B Vaccination Coverage and Serologic Evidence of Immunity Among US-Born Children and Adolescents From 1999 to 2016 | 5.2 | 43 | Citations (PDF) |
| 61 | Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies | 3.1 | 9 | Citations (PDF) |
| 62 | Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease | 3.7 | 61 | Citations (PDF) |
| 63 | Safety, Pharmacokinetics and Pharmacodynamics of Selgantolimod, an Oral Toll-Like Receptor 8 Agonist: A Phase Ia Study in Healthy Subjects | 1.8 | 14 | Citations (PDF) |
| 64 | The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C | 1.1 | 1 | Citations (PDF) |
| 65 | Graft-vs-Host Disease After Liver Transplantation: A Diagnostic and Management Challenge | 0.4 | 4 | Citations (PDF) |
| 66 | Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | 10.4 | 299 | Citations (PDF) |
| 67 | Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand | 1.2 | 1 | Citations (PDF) |
| 68 | Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study | 7.4 | 333 | Citations (PDF) |
| 69 | Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients | 2.7 | 21 | Citations (PDF) |
| 70 | Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non‐alcoholic steatohepatitis or alcoholic liver disease: a 20‐year experience from a national programme | 0.7 | 14 | Citations (PDF) |
| 71 | Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection | 3.0 | 17 | Citations (PDF) |
| 72 | Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials | 14.9 | 32 | Citations (PDF) |
| 73 | Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017 | 1.3 | 20 | Citations (PDF) |
| 74 | Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy | 7.4 | 115 | Citations (PDF) |
| 75 | Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand | 1.6 | 44 | Citations (PDF) |
| 76 | Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis | 1.2 | 40 | Citations (PDF) |
| 77 | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease | 2.1 | 16 | Citations (PDF) |
| 78 | Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission | 14.9 | 509 | Citations (PDF) |
| 79 | Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial | 14.9 | 58 | Citations (PDF) |
| 80 | Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection | 9.5 | 175 | Citations (PDF) |
| 81 | Hepatitis C Virus Eradication with New Interferon‐Free Treatment Improves Metabolic Profile in Hepatitis C Virus‐Related Liver Transplant Recipients | 1.6 | 39 | Citations (PDF) |
| 82 | ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B | 3.1 | 36 | Citations (PDF) |
| 83 | 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection | 7.4 | 401 | Citations (PDF) |
| 84 | Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection | 19.4 | 423 | Citations (PDF) |
| 85 | Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial | 14.9 | 273 | Citations (PDF) |
| 86 | Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3 | 1.9 | 5 | Citations (PDF) |
| 87 | Effects of Treatment of Chronic Hepatitis B Virus Infection on Patient-Reported Outcomes | 5.3 | 40 | Citations (PDF) |
| 88 | High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis | 7.4 | 151 | Citations (PDF) |
| 89 | Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6 | 7.4 | 41 | Citations (PDF) |
| 90 | Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study | 2.2 | 71 | Citations (PDF) |
| 91 | Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy | 2.2 | 24 | Citations (PDF) |
| 92 | Short‐Duration AL‐335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis | 9.5 | 9 | Citations (PDF) |
| 93 | Intention-to-treat analysis of liver transplantation, resection and thermal ablation for hepatocellular carcinoma in a single centre | 0.2 | 7 | Citations (PDF) |
| 94 | Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment | 1.6 | 12 | Citations (PDF) |
| 95 | Hepatic venous outflow obstruction in piggyback liver transplantation: single centre experience | 0.8 | 16 | Citations (PDF) |
| 96 | Management of hepatitis C virus infection in the Asia-Pacific region: an update | 14.9 | 49 | Citations (PDF) |
| 97 | Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study | 14.9 | 1,813 | Citations (PDF) |
| 98 | Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B | 10.4 | 51 | Citations (PDF) |
| 99 | Hepatitis C virus infection | 37.9 | 484 | Citations (PDF) |
| 100 | Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis | 7.4 | 285 | Citations (PDF) |
| 101 | Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen | 9.5 | 82 | Citations (PDF) |
| 102 | A Diacylglycerol Transferase 1 Inhibitor Is a Potent Hepatitis C Antiviral in Vitro but Not in Patients in a Randomized Clinical Trial | 2.8 | 14 | Citations (PDF) |
| 103 | Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment | 19.4 | 372 | Citations (PDF) |
| 104 | The emergence of NS5B resistance associated substitution S282T after sofosbuvir‐based treatment | 3.3 | 41 | Citations (PDF) |
| 105 | Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study | 7.4 | 62 | Citations (PDF) |
| 106 | Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2 | 0.7 | 15 | Citations (PDF) |
| 107 | Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction | 0.6 | 5 | Citations (PDF) |
| 108 | Sofosbuvir/Velpatasvir Plus GS-9857 (100 Milligrams) for 6, 8, or 12 Weeks in Genotype 1-6 Hepatitis C Virus (HCV)-Infected Patients: An Integrated Analysis of Safety and Efficacy From Two Phase 2 Studies | 0.7 | 0 | Citations (PDF) |
| 109 | Ledipasvir and Sofosbuvir for HCV Infection in Patients Coinfected with HBV | 1.8 | 48 | Citations (PDF) |
| 110 | HBsAg loss in a New Zealand community study with 28-year follow-up: rates, predictors and long-term outcomes | 3.2 | 23 | Citations (PDF) |
| 111 | Incidence of HCV Reinfection among Treated Individuals with Recently Acquired Infection | 7.4 | 2 | Citations (PDF) |
| 112 | Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study | 9.5 | 51 | Citations (PDF) |
| 113 | High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis | 0.9 | 95 | Citations (PDF) |
| 114 | Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders | 10.4 | 66 | Citations (PDF) |
| 115 | Development of sofosbuvir for the treatment of hepatitis C virus infection | 2.6 | 44 | Citations (PDF) |
| 116 | Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis | 2.4 | 13 | Citations (PDF) |
| 117 | Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection | 7.4 | 194 | Citations (PDF) |
| 118 | Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis | 9.5 | 241 | Citations (PDF) |
| 119 | Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years | 3.2 | 55 | Citations (PDF) |
| 120 | Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection | 0.9 | 180 | Citations (PDF) |
| 121 | Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation | 0.9 | 325 | Citations (PDF) |
| 122 | Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy | 7.4 | 66 | Citations (PDF) |
| 123 | Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study | 0.9 | 321 | Citations (PDF) |
| 124 | Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study | 10.4 | 29 | Citations (PDF) |
| 125 | ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection | 1.5 | 5 | Citations (PDF) |
| 126 | Efficacy and Safety of Danoprevir-Ritonavir plus Peginterferon Alfa-2a–Ribavirin in Hepatitis C Virus Genotype 1 Prior Null Responders | 2.4 | 20 | Citations (PDF) |
| 127 | Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials | 3.8 | 216 | Citations (PDF) |
| 128 | VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection | 1.0 | 14 | Citations (PDF) |
| 129 | Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients With Lamivudine-Resistant Chronic Hepatitis B | 0.9 | 150 | Citations (PDF) |
| 130 | Efficacy of Nucleotide Polymerase Inhibitor Sofosbuvir Plus the NS5A Inhibitor Ledipasvir or the NS5B Non-Nucleoside Inhibitor GS-9669 Against HCV Genotype 1 Infection | 0.9 | 209 | Citations (PDF) |
| 131 | Effects of Sofosbuvir-Based Treatment, With and Without Interferon, on Outcome and Productivity of Patients With Chronic Hepatitis C | 5.3 | 88 | Citations (PDF) |
| 132 | Minimal impact of sofosbuvir and ribavirin on health related quality of life in Chronic Hepatitis C (CH-C) | 7.4 | 90 | Citations (PDF) |
| 133 | No Resistance to Tenofovir Disoproxil Fumarate Through 96 Weeks of Treatment in Patients With Lamivudine-Resistant Chronic Hepatitis B | 5.3 | 39 | Citations (PDF) |
| 134 | Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA | 0.9 | 173 | Citations (PDF) |
| 135 | Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial | 0.9 | 245 | Citations (PDF) |
| 136 | Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis | 5.3 | 20 | Citations (PDF) |
| 137 | Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection | 1.4 | 273 | Citations (PDF) |
| 138 | Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B | 1.4 | 30 | Citations (PDF) |
| 139 | Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study | 45.2 | 1,714 | Citations (PDF) |
| 140 | Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection | 19.4 | 1,664 | Citations (PDF) |
| 141 | Future perspectives: towards interferon-free regimens for HCV | 1.8 | 17 | Citations (PDF) |
| 142 | Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C | 0.9 | 93 | Citations (PDF) |
| 143 | Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B | 0.9 | 429 | Citations (PDF) |
| 144 | Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients | 7.4 | 51 | Citations (PDF) |
| 145 | Validation of the “Metroticket” predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma | 7.4 | 38 | Citations (PDF) |
| 146 | Future hepatitis C virus treatment: interferon‐sparing combinations | 3.1 | 37 | Citations (PDF) |
| 147 | Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus Infection | 1.4 | 92 | Citations (PDF) |
| 148 | Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B | 7.4 | 186 | Citations (PDF) |
| 149 | 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B | 0.9 | 547 | Citations (PDF) |
| 150 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | 3.2 | 844 | Citations (PDF) |
| 151 | Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B | 19.4 | 1,125 | Citations (PDF) |
| 152 | Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine | 2.0 | 176 | Citations (PDF) |
| 153 | Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B | 19.4 | 753 | Citations (PDF) |
| 154 | Liver transplantation in Jehovah's Witness patients in Australasia | 1.4 | 8 | Citations (PDF) |
| 155 | Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in Polynesians | 1.1 | 24 | Citations (PDF) |
| 156 | Liver Resection for Hepatocellular Carcinoma in a Hepatitis B Endemic Area | 1.2 | 242 | Citations (PDF) |
| 157 | A Technique for Controlled Partial Closure of a Transjugular Intrahepatic Portosystemic Shunt Tract in a Patient with Hepatic Encephalopathy | 1.1 | 16 | Citations (PDF) |
| 158 | Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update | 3.1 | 318 | Citations (PDF) |
| 159 | Pre- and postoperative immunonutrition in patients undergoing liver transplantation: a pilot study of safety and efficacy | 3.2 | 104 | Citations (PDF) |
| 160 | Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B | 19.4 | 1,523 | Citations (PDF) |
| 161 | Renal transplantation in chronic hepatitis C | 1.8 | 4 | Citations (PDF) |
| 162 | Management of chronic viral hepatitis before and after renal transplantation | 1.7 | 152 | Citations (PDF) |
| 163 | Treatment of recurrent hepatitis C | 1.6 | 46 | Citations (PDF) |
| 164 | Peginterferon Alfa-2a in Patients with Chronic Hepatitis C | 19.4 | 1,192 | Citations (PDF) |
| 165 | Pre- and post-transplant treatment of hepatitis C | 1.8 | 2 | Citations (PDF) |
| 166 | Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients | 45.2 | 489 | Citations (PDF) |
| 167 | Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation | 0.9 | 83 | Citations (PDF) |
| 168 | Nodular regenerative hyperplasia of the liver graft after liver transplantation | 9.5 | 17 | Citations (PDF) |
| 169 | No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection | 3.8 | 61 | Citations (PDF) |
| 170 | Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment | 2.6 | 9 | Citations (PDF) |
| 171 | Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial | 3.6 | 1 | Citations (PDF) |
| 172 | A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D | 19.4 | 18 | Citations (PDF) |
| 173 | A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants | 1.8 | 2 | Citations (PDF) |
| 174 | Effect of tiomolibdate choline on copper balance in patients with Wilson disease: An open-label phase 2 trial | 3.3 | 0 | Citations (PDF) |
| 175 | WED-602 Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level | 7.4 | 0 | Citations (PDF) |
| 176 | WED-580 Baseline and on-treatment characteristics of HBeAg-positive patients and correlates of HBeAg loss following GS-2829 and GS-6779 therapeutic vaccination in virally suppressed patients with chronic hepatitis B | 7.4 | 0 | Citations (PDF) |
| 177 | WED-581 SOLSTICE week 48 subgroup analysis: Impact of BMI on ALT normalization after successful viral control in participants with chronic hepatitis delta virus infection treated with tobevibart plus elebsiran | 7.4 | 0 | Citations (PDF) |
| 178 | OS-057 Tiomolibdate choline stabilizes liver disease and improves neurological symptoms as well as quality-of-life in treatmentexperienced Wilson disease patients | 7.4 | 0 | Citations (PDF) |
| 179 | LBO-003 Tune-401: a first-in-class epigenetic silencer of HBV demonstrates deep and durable antiviral activity in the phase 1b/2a proof of concept Tune-401-001 study | 7.4 | 0 | Citations (PDF) |
| 180 | WED-579 Safety, pharmacokinetics, and pharmacodynamic activity of ABI-6250, a first in class oral hepatitis D virus entry inhibitor in healthy subjects: interim results from a randomized, blinded, phase 1a study | 7.4 | 0 | Citations (PDF) |
| 181 | OS-073 A single VRON-0200 prime dose, followed by a monthly antiviral combination regimen, resulted in rapid, profound, and durable HBsAg declines in chronically hepatitis B-infected patients | 7.4 | 0 | Citations (PDF) |
| 182 | GS-012 Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: week 96 endpoint results from the phase 2 SOLSTICE trial | 7.4 | 1 | Citations (PDF) |
| 183 | LBP-043 First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV | 7.4 | 0 | Citations (PDF) |
| 184 | FRI-594 Safety and efficacy of long-term tenofovir alafenamide treatment in patients aged 60 years and older with chronic hepatitis B: experience from two phase 3 clinical trials | 7.4 | 0 | Citations (PDF) |
| 185 | WED-586 Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection | 7.4 | 0 | Citations (PDF) |
| 186 | GS-001 Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-Well phase 3 trials | 7.4 | 0 | Citations (PDF) |
| 187 | WED-597 Safety, pharmacokinetics, pharmacodynamics, and antiviral activity of cavrotolimod, alone and in combination with low-dose nivolumab, for the treatment of chronic hepatitis B | 7.4 | 0 | Citations (PDF) |
| 188 | LBP-021 24-week safety and efficacy of brelovitug monotherapy for the treatment of chronic hepatitis D: data from phase 2b of AZURE-1 | 7.4 | 0 | Citations (PDF) |
| 189 | WED-578 Transcriptomic profiling reveals distinct immune signatures in chronic hepatitis B and identifies blood transcriptional modules associated with hepatitis B e antigen loss following therapeutic vaccination with GS-2829 and GS-6779 | 7.4 | 0 | Citations (PDF) |
